Iovance lifts 2026 revenue guidance to $410-420 million
The company points to strong U.S. uptake of Amtagvi and Proleukin, raising the midpoint by $55 million from its prior range.
Iovance Biotherapeutics announced on September 29, 2026 that it has increased its full year 2026 total revenue guidance to a range of $410 to $420 million, up from a prior range of $350 to $370 million, citing strong U.S. demand for Amtagvi (lifileucel) and Proleukin.1
The company said the new midpoint is $55 million, or roughly 15%, above the previous guidance range, and implies nearly 60% annual growth in total revenue.1
Interim President and Chief Executive Officer Frederick Vogt attributed the update to a record second quarter and continued demand for Amtagvi and Proleukin, which led the company to raise its full year guidance by $55 million at the midpoint.1 Vogt added that rising patient demand and the current manufacturing schedule give the company visibility into third and fourth quarter revenues.1 He also said lifileucel continues to move forward in registrational programs for new solid tumor indications, while manufacturing and operational efficiencies are helping push the company toward profitability.1
Iovance said its second quarter 2026 total product revenue reached $99.3 million, a company record, and its authorized treatment center network has grown to about 100 sites, with plans to expand to at least 110 by the end of 2026.1 The company said it plans to release its third quarter 2026 financial results in early November 2026.1
The filing noted that this update completes the guidance review the company announced alongside its second quarter 2026 results.1 Iovance describes Amtagvi as the first FDA-approved, one-time treatment for previously treated advanced melanoma, now cleared in three global markets and offered at close to 100 authorized treatment centers.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.